Stock Price: $1.71 • 3/5/25
GeoVax Labs is a biotech company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company uses its proprietary MVA-VLP technology to create innovative vaccine candidates.
With rising concerns over measles outbreaks and the potential spread of bird flu, vaccine developers are in focus. GeoVax is advancing a broad vaccine pipeline, including candidates for both viral threats.
Last year, the company secured funding and partnerships to accelerate its vaccine programs, positioning itself for potential regulatory approvals. Its MVA-based technology offers a differentiated approach that could attract more interest.
Opinion: GeoVax remains an under-the-radar player in the vaccine space, and any major development could push it into the spotlight.